> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Endo Settles ‘Pay-for-Delay’ Charges
- URL: https://www.fdaweb.com/endo-settles-pay-for-delay-charges/
- Published: 2017-01-25T12:00:00.000Z
- Updated: 2026-09-14T22:02:57.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137818

The Federal Trade Commission has filed a federal court stipulated order resolving charges that Endo Pharmaceuticals and Endo International violated antitrust laws by using so-called pay-for-delay settlements to block consumer access to generic versions of its Lidoderm topical patch indicated to relieve post-herpetic neuralgia and Opana ER, an extended-release opioid. A commission [statement](https://www.ftc.gov/news-events/press-releases/2017/01/endo-pharmaceuticals-inc-agrees-abandon-anticompetitive-pay-delay?ref=fdaweb.com) says the action resolves charges originally filed 3/2016.

In a related matter, FTC refiled charges against Watson Laboratories and its former parent, Allergan, for illegally blocking a lower-cost generic version of Lidoderm when it entered into a pay-for-delay agreement with Endo. The agency also issued an administrative complaint against Impax Laboratories for engaging in similar conduct relating to Opana ER.

The proposed Endo order prohibits the company and its subsidiaries from entering into this type of anticompetitive patent settlements that FTC charged Endo used to eliminate the risk of generic competition, including its use of “no-authorized generic”, in which an innovator drug company agrees not to compete with an authorized generic version of a drug for a period of time.

“Because Endo is now prohibited by commission order from entering into pay-for-delay settlements,” the statement says, “the order also releases Endo from liability for its use of reverse-payment settlement agreements concerning the branded drug AndroGel.”